A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors

NCT ID: NCT04047290

Last Updated: 2025-02-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-09-20
• Study Completion Date: 2024-02-27

Brief Summary

This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112, a PD-1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumor malignancies. The study consists of a dose escalation phase (Phase 1a) to determine the maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D) for AK112 as a single agent, and a dose expansion phase (Phase 1b) in subjects with specific tumor types which will characterize treatment of AK112 as a single agent at the MTD or RP2D.

Conditions

Neoplasms Malignant

Study Design

• Allocation Method: NA
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

AK112

AK112 IV every 2 weeks (q2w) or every 3 weeks (q3w)

Group Type: EXPERIMENTAL

AK112

Intervention Type: DRUG

AK112 is a PD1/VEGF bispecific antibody.

Interventions

AK112

AK112 is a PD1/VEGF bispecific antibody.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Written and signed informed consent and any locally required authorization obtained from the subject/legal representative.
• In dose-escalation cohorts (Phase 1a), histologically or cytologically documented advanced or metastatic solid tumor that is refractory/relapsed to standard therapies, or for which no effective standard therapy is available, or the subject refuses standard therapy.
• In the dose-expansion cohorts (Phase 1b), histologically or cytologically confirmed selected advanced solid tumors.
• Subject must have at least one measurable lesion according to RECIST Version1.1.
• Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
• Available archived tumor tissue sample to allow for correlative biomarker studies. If unavailable or unsuitable, the subject must consent and undergo fresh tumor biopsy.
• Adequate organ function.
• Subjects with central nervous system (CNS) metastases must have been treated, be asymptomatic.
• Females of childbearing potential and non-sterilized males who are sexually active must use an effective method of contraception from screening until 120 days after final dose of investigational product or women of non child bearing potential.
• Life expectancy ≥12 weeks.

Exclusion Criteria

• History of severe hypersensitivity reactions to other mAbs.
• Prior malignancy active within the previous 3 years except for the tumor for which a subject is enrolled in the study, and locally curable cancers that have been apparently cured, (e.g. basal cell skin cancer, or carcinoma in situ of the cervix or breast).
• For subjects enrolled in the dose escalation phase, having received prior anti-PD-1, anti-PD-L1, anti-CTLA-4 or any other immunotherapy or immune-oncology (IO) agent within 28 days of commencing treatment with AK112 or experienced a toxicity that led to permanent discontinuation of prior immunotherapy. All AEs while receiving prior immunotherapy have not completely resolved or resolved to Grade 1 prior to screening, required the use of additional immunosuppression other than corticosteroids
• Receiving any immunotherapy, conventional or investigational systemic anticancer therapy within 4 weeks prior to the first dose
• Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment (hormones use for non-cancer related conditions is acceptable).
• Subjects with clinically significant cardiovascular disease
• Subjects with a condition requiring systemic treatment with either corticosteroid (> 10 mg daily ) or other immunosuppressive medications within 2 weeks of study drug administration.
• Current or recent use of aspirin (> 325 mg/day) or treatment with dipyramidole, ticlopidine, clopidogrel, and cilostazol.
• Current unstable of full-dose oral or parenteral anticoagulants or thrombolytic agents for > 2 weeks prior to the first dose of AK112
• Active or prior documented autoimmune disease within the past 2 years or conditions not expected to recur in the absence of an external trigger)
• Active or prior documented inflammatory bowel disease
• History of primary immunodeficiency.
• History of organ transplant.
• Known allergy or reaction to any component of the AK112 formulation.
• History of interstitial lung disease or non-infectious pneumonitis except for those induced by radiation therapies.
• Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5.0 Grade 0 or 1
• Major surgical procedure within 30 days prior to the first dose of AK112 or still recovering from prior surgery.
• Known history of HIV.
• Known active hepatitis B or C infections. Note: Subjects with HCC and positive HBsAg result are eligible if the subjects were treated with antiviral therapy and HBV viral load less than 500 IU/mL prior to first dose of AK112.
• An active infection requiring systemic therapy
• Received live attenuated vaccination within 30 days prior to the first dose of AK112.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Akesobio Australia Pty Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Border Medical Oncology

Albury, New South Wales, Australia

Scientia Clinical Research Ltd

Randwick, New South Wales, Australia

Blacktown Hospital

Sydney, New South Wales, Australia

ICON Cancer Foundation

South Brisbane, Queensland, Australia

Adelaide Cancer Centre

Kurralta Park, South Australia, Australia

Monash Health

Clayton, Victoria, Australia

Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia

Countries

Australia

References

Frentzas S, Austria Mislang AR, Lemech C, Nagrial A, Underhill C, Wang W, Wang ZM, Li B, Xia Y, Coward JIG. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors. J Immunother Cancer. 2024 Apr 19;12(4):e008037. doi: 10.1136/jitc-2023-008037.

Reference Type: DERIVED

PMID: 38642937 (View on PubMed)

Related Links

https://pubmed.ncbi.nlm.nih.gov/38642937/

Related Info

Other Identifiers

AK112-101

Identifier Type: -

Identifier Source: org_study_id